Nyxoah to Participate in the 17th Annual Wells Fargo Securities Healthcare Conference

Rhea-AI Summary

Nyxoah, a medical technology company specializing in solutions for Obstructive Sleep Apnea (OSA), will participate in the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022, in Everett, MA. Management will conduct one-on-one meetings with investors on September 9. The announcement comes as Nyxoah continues to advance its Genio® system, a revolutionary treatment for OSA. With CE Mark approval since 2019 and ongoing studies for FDA approval, Nyxoah aims to improve patient outcomes and expand its market presence.

Nyxoah to Participate in the 17^th Annual Wells Fargo Securities Healthcare Conference

Mont-Saint-Guibert, Belgium – August 18, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the 17^th Annual Wells Fargo Securities Healthcare Conference, which takes place September 7-9, 2022, in Everett, MA. Nyxoah management will host one-on-one meetings with investors on Friday, September 9.

Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

• ENGLISH_Wells Fargo Healthcare Conference PR_FINAL

FAQ

What events will Nyxoah participate in September 2022?

Nyxoah will participate in the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022.

When will Nyxoah hold one-on-one meetings with investors?

Nyxoah will host one-on-one meetings with investors on September 9, 2022, during the healthcare conference.

What is the Genio® system developed by Nyxoah?

The Genio® system is a patient-centered, leadless, and battery-free hypoglossal neurostimulation therapy for treating Obstructive Sleep Apnea.

What is the significance of the CE Mark for Nyxoah?

The CE Mark, obtained in 2019, signifies that Nyxoah's Genio® system meets European health and safety standards for medical devices.

Is Nyxoah pursuing FDA approval?

Yes, Nyxoah is conducting the DREAM IDE pivotal study to gain FDA approval for U.S. commercialization of its Genio® system.